<DOC>
	<DOCNO>NCT00813332</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Endostar ( Recombinant Human Endostatin ) combine Docetaxel single Docetaxel multi-center , double-blinding , randomize control , phase Ⅳ clinical trial NSCLC case obvious progressive disease intolerant adverse effect first-line chemotherapy .</brief_summary>
	<brief_title>Second-line Therapy Study Combined Chemotherapy Endostar Patients With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The combinative therapy Endostar , Vinorelbine cisplatin show increase response rate survival patient ( pt ) advance NSCLC sFDA-approved indication . However , limited data safety efficacy Endostar combination widely use chemotherapy doublet NSCLC . Clinical data prove Endostar wild spectrum safe antiangiogenesis factor could suppress almost 65 kind tumor mass animal model affect 12 percent human genome . In clinical trial , 160 patient enrollment , give Docetaxel ( 75mg/m2 , iv , d1 , every 3 week ) plus Endostar ( 7.5mg/m2/day , iv , d1-d14 , every 3 week ) Docetaxel placebo . We 'll evaluate efficacy safety Docetaxel plus Endostar treatment NSCLC hope provide promise regimen advance lung cancer patient .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . Age 1875 year old , males female ; 2 . Patients NSCLC confirm histopathology cytology need secondline chemotherapy , include progressive disease case 3 month posterior end firstline chemotherapy ( least 4 cycle do ) case intolerant adverse effect firstline chemotherapy ( least 4 cycle do ) ; neoadjuvant chemotherapy target therapy ( EFGRTKIs ) serve firstline chemotherapy ; 3 month clearance need neoadjuvant chemotherapy 1 month target firstline chemotherapy ; 3 . Local advance metastatic case tumor foci evaluate CT , MRI PETCT ; least one diameter ≥ 1 cm ( include metastatic lymph node ) confirm CT scan ≥ 1 cm spin CT PETCT ) ; 4 . No contraindication chemotherapy , normal peripheral hemogram , renal hepatic function : Peripheral hemogram : WBC≥4.0×109/L，PLT≥80×109/L，Hgb≥90g/L； Renal function : serum BUN creatinine ≤1.0×UNL ; Hepatic function : transaminase≤1.5×UNL , BIL≤×UNL ; 5 . Karnofsky performance scale≥60 ECOG performance scale≤ 2 ; expect survival time≥3 month ; 6 . No allergic history biological agent taxane agent ; 7 . Patients voluntary participate sign inform content . 1 . Pregnant breastfeeding female ; female reproductive ability take contraception method ; 2 . With severe acute infection uncontrolled ; purulent chronic infection wound difficult recover ; 3 . With history severe heart disease , include congestive heart failure , uncontrolled arrhythmia high risk , unstable angina pectoris , myocardial infarction , severe cardiac valvular disease refractory hypertension ; 4 . Patients uncontrolled neurological , mental disease psychosis , patient poor compliance coordinate therapy describe treatment response ; 5 . Uncontrolled brain metastasis patient obvious manifestation intracranial hypertension neurological mental disorder ; 6 . Uncontrolled diabetes contraindication corticoid agent ; 7 . Obvious hemorrhage tendency ; 8 . Allergic drug trial ; 9 . Patients second tumor ; 10 . Patients participate clinical trial ; 11 . Patients treat Endostar Docetaxel ( exclude neochemotherapy ) include combination chemotherapy previously ; 12 . Foci evaluate response trial treat radiation 6 month . 13 . Other condition regard exclusion trialists .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Endostar</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Combined therapy</keyword>
	<keyword>second-line chemotherapy</keyword>
</DOC>